Associated High Confidence AOPs |
---|
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:17 | Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.1 | KE:1392 | Oxidative Stress |
AOP:34 | LXR activation leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.08 | KE:116 | Activation, FAS |
AOP:54 | Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.1 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:107 | Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat | Cancer; Gastrointestinal System Disease | Under Review | 0.2 | KE:1214 | Altered gene expression specific to CAR activation, Hepatocytes |
AOP:110 | Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine System Disease | - | 0.14 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive System Disease; Cancer | - | 0.17 | KE:111 | Agonism, Estrogen receptor |
AOP:123 | Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription | Unclassified | - | 0.09 | KE:802 | Increased, HIF-1 alpha transcription |
AOP:134 | Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.11 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:144 | Endocytic lysosomal uptake leading to liver fibrosis | Gastrointestinal System Disease | Under Review | 0.11 | KE:1494 | Leukocyte recruitment/activation |
AOP:173 | Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | WPHA/WNT Endorsed | 0.12 | KE:1497 | Increased, recruitment of inflammatory cells |
AOP:176 | Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:188 | Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:192 | Pendrin inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:193 | Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:206 | Peroxisome proliferator-activated receptors γ inactivation leading to lung fibrosis | Musculoskeletal System Disease; Respiratory System Disease | Under Development | 0.17 | KE:1271 | Activation of TGF-β signaling |
AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive System Disease | - | 0.12 | KE:1280 | Activation, HIF-1 |
AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal System Disease | WPHA/WNT Endorsed | 0.2 | KE:1392 | Oxidative Stress |
AOP:260 | CYP2E1 activation and formation of protein adducts leading to neurodegeneration | Nervous System Disease | - | 0.14 | KE:1392 | Oxidative Stress |
AOP:288 | Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals) | Endocrine System Disease | - | 0.12 | KE:1614 | Decrease, androgen receptor activation |
AOP:293 | Increased DNA damage leading to increased risk of breast cancer | Genetic Disease; Thoracic Disease; Cancer | Under Development | 0.11 | KE:1494 | Leukocyte recruitment/activation |
AOP:294 | Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | Genetic Disease; Thoracic Disease; Cancer | Under Development | 0.11 | KE:1494 | Leukocyte recruitment/activation |
AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | 0.14 | KE:1497 | Increased, recruitment of inflammatory cells |
AOP:305 | 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | 0.4 | KE:1614 | Decrease, androgen receptor activation |
KE:286 | Altered, Transcription of genes by the androgen receptor | |||||
AOP:347 | Toll-like receptor 4 activation and peroxisome proliferator-activated receptor gamma inactivation leading to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | - | 0.11 | KE:1283 | Activation, TGF-beta pathway |
AOP:409 | Frustrated phagocytosis leads to malignant mesothelioma | Cancer | - | 0.12 | KE:1497 | Increased, recruitment of inflammatory cells |
AOP:437 | Inhibition of mitochondrial electron transport chain (ETC) complexes leading to kidney toxicity | Urinary System Disease | Under Development | 0.2 | KE:1392 | Oxidative Stress |
AOP:438 | reactive oxygen species generation leading to increased cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.08 | KE:1392 | Oxidative Stress |
AOP:440 | Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia | Benign Neoplasm; Endocrine System Disease; Reproductive System Disease; Reproductive System Disease; Cancer; Endocrine System Disease | Under Development | 0.11 | KE:1973 | Increased, estrogens |
AOP:444 | Ionizing radiation leads to reduced reproduction in Eisenia fetida via reduced spermatogenesis and cocoon hatchability | Unclassified | - | 0.11 | KE:1392 | Oxidative Stress |
AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory System Disease | - | 0.2 | KE:18 | Activation, AhR |
KE:165 | Activation, Long term AHR receptor driven direct and indirect gene expression changes | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:1392 | Oxidative Stress | |||||
AOP:448 | ROS, inflammation, and activation of nAChR lead to increased incidence of cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.06 | KE:1392 | Oxidative Stress |
AOP:449 | Ceramide synthase inhibition leading to neural tube defects | Neural Tube Defect | - | 0.14 | KE:1502 | Histone deacetylase inhibition |
AOP:450 | Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality | Nervous System Disease | - | 0.14 | KE:1392 | Oxidative Stress |
AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | 0.11 | KE:1497 | Increased, recruitment of inflammatory cells |
AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory System Disease | - | 0.09 | KE:1392 | Oxidative Stress |
AOP:453 | Reactive oxygen species and subsequent oxidative stress lead to increased incidence of digestive morbidity and mortality in the general population | Gastrointestinal System Disease | - | 0.08 | KE:1392 | Oxidative Stress |
AOP:457 | Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine | Inherited Metabolic Disorder | - | 0.33 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:1392 | Oxidative Stress | |||||
AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal System Disease | - | 0.09 | KE:1392 | Oxidative Stress |
AOP:464 | Calcium overload in dopaminergic neurons of the substantia nigra leading to parkinsonian motor deficits | Nervous System Disease | - | 0.05 | KE:1392 | Oxidative Stress |
AOP:465 | Alcohol dehydrogenase leading to reproductive dysfunction | Unclassified | - | 0.12 | KE:748 | Increased, Estrogen receptor (ER) activity |
AOP:468 | Binding of SARS-CoV-2 to ACE2 leads to hyperinflammation (via cell death) | Unclassified | - | 0.12 | KE:1497 | Increased, recruitment of inflammatory cells |
AOP:469 | Reactive oxygen speicies overproduction leading to increased digestive morbidity and mortality in generation population | Gastrointestinal System Disease | - | 0.08 | KE:1392 | Oxidative Stress |
AOP:470 | Deposition of energy leads to abnormal vascular remodeling | Cardiovascular System Disease | Under Review | 0.12 | KE:1392 | Oxidative Stress |
AOP:478 | Deposition of energy leading to occurrence of cataracts | Nervous System Disease; Monogenic Disease | Under Review | 0.1 | KE:1392 | Oxidative Stress |
AOP:479 | Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress | Cardiovascular System Disease; Thoracic Disease | Under Development | 0.14 | KE:1392 | Oxidative Stress |
AOP:482 | Deposition of energy leading to occurrence of bone loss | Musculoskeletal System Disease | Under Review | 0.14 | KE:1392 | Oxidative Stress |
AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental Disorder Of Mental Health | Under Review | 0.12 | KE:1392 | Oxidative Stress |
AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive Disorder | - | 0.14 | KE:1392 | Oxidative Stress |
AOP:490 | Co-activation of IP3R and RyR leads to reduced IQ through non-cholinergic mechanisms | Developmental Disorder Of Mental Health | - | 0.18 | KE:2123 | decreased, Bcl-2 expression |
KE:2124 | increased, Bax expression | |||||
AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired Metabolic Disease | - | 0.1 | KE:1497 | Increased, recruitment of inflammatory cells |
AOP:495 | Androgen receptor activation leading to prostate cancer | Reproductive System Disease; Cancer | - | 0.11 | KE:286 | Altered, Transcription of genes by the androgen receptor |
AOP:496 | Androgen receptor agonism leading to reproduction dysfunction (in zebrafish) | Unclassified | - | 0.1 | KE:286 | Altered, Transcription of genes by the androgen receptor |
AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited Metabolic Disorder; Disease Of Metabolism | - | 0.12 | KE:1392 | Oxidative Stress |
AOP:501 | Excessive iron accumulation leading to neurological disorders | Nervous System Disease | - | 0.25 | KE:1392 | Oxidative Stress |
AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | 0.2 | KE:1392 | Oxidative Stress |
AOP:507 | Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway | Cardiovascular System Disease | - | 0.17 | KE:1392 | Oxidative Stress |
AOP:509 | Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction | Cardiovascular System Disease | - | 0.14 | KE:1392 | Oxidative Stress |
AOP:510 | Demethylation of PPAR promotor leading to vascular disrupting effects | Cardiovascular System Disease | - | 0.1 | KE:1392 | Oxidative Stress |
AOP:511 | The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects | Cardiovascular System Disease | - | 0.12 | KE:2171 | Activated BMP/TGF-beta pathway |
KE:1392 | Oxidative Stress | |||||
AOP:521 | Essential element imbalance leads to reproductive failure via oxidative stress | Unclassified | - | 0.14 | KE:1392 | Oxidative Stress |
AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | 0.17 | KE:1392 | Oxidative Stress |
AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental Disorder Of Mental Health | - | 0.11 | KE:1392 | Oxidative Stress |
AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.11 | KE:1392 | Oxidative Stress |
AOP:541 | Excessive ROS generation leading to increased incidence of vascular calcification by VSMC phenotype switching | Cardiovascular System Disease | - | 0.08 | KE:1392 | Oxidative Stress |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:43 | Disruption of VEGFR Signaling Leading to Developmental Defects | Unclassified | WPHA/WNT Endorsed | 0.2 | KE:1001 | Increased, Developmental Defects |
AOP:504 | SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level | Unclassified | - | 0.33 | KE:1065 | Activation, estrogen receptor alpha |
AOP:561 | Aromatase induction leading to estrogen receptor alpha activation via increased estradiol | Unclassified | - | 0.2 | KE:1065 | Activation, estrogen receptor alpha |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:19 | Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) | Reproductive System Disease | - | 0.4 | KE:26 | Antagonism, Androgen receptor |
KE:286 | Altered, Transcription of genes by the androgen receptor | |||||
AOP:21 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 | Unclassified | WPHA/WNT Endorsed | 0.2 | KE:18 | Activation, AhR |
AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal System Disease | Under Development | 0.12 | KE:41 | Inhibition, Bile Salt Export Pump (ABCB11) |
AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal System Disease | Under Review | 0.2 | KE:165 | Activation, Long term AHR receptor driven direct and indirect gene expression changes |
AOP:42 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | WPHA/WNT Endorsed | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:279 | Thyroperoxidase, Inhibition | |||||
AOP:108 | Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | - | 0.17 | KE:724 | Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme |
AOP:111 | Decrease in androgen receptor activity leading to Leydig cell tumors (in rat) | Cancer; Reproductive System Disease | - | 0.2 | KE:1614 | Decrease, androgen receptor activation |
AOP:119 | Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine System Disease | - | 0.29 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:279 | Thyroperoxidase, Inhibition | |||||
AOP:128 | Kidney dysfunction by decreased thyroid hormone | Urinary System Disease | Under Development | 0.09 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:131 | Aryl hydrocarbon receptor activation leading to uroporphyria | Inherited Metabolic Disorder | WPHA/WNT Endorsed | 0.17 | KE:18 | Activation, AhR |
AOP:150 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF | Unclassified | WPHA/WNT Endorsed | 0.14 | KE:18 | Activation, AhR |
AOP:151 | AhR activation leading to preeclampsia | Cardiovascular System Disease | Under Development | 0.14 | KE:18 | Activation, AhR |
AOP:159 | Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:279 | Thyroperoxidase, Inhibition | |||||
AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive System Disease; Cancer | - | 0.29 | KE:1064 | prepubertal increase, Estrogen receptor (ER) activity |
KE:1065 | Activation, estrogen receptor alpha | |||||
AOP:175 | Thyroperoxidase inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.5 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:279 | Thyroperoxidase, Inhibition | |||||
AOP:209 | Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP | Gastrointestinal System Disease | - | 0.12 | KE:1286 | Down Regulation, GSS and GSTs gene |
AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive System Disease | WPHA/WNT Endorsed | 0.17 | KE:1502 | Histone deacetylase inhibition |
AOP:271 | Inhibition of thyroid peroxidase leading to impaired fertility in fish | Unclassified | Under Development | 0.4 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:279 | Thyroperoxidase, Inhibition | |||||
AOP:274 | Histone deacetylase inhibition leads to impeded craniofacial development | Musculoskeletal System Disease | - | 0.25 | KE:1502 | Histone deacetylase inhibition |
AOP:275 | Histone deacetylase inhibition leads to neural tube defects | Neural Tube Defect | - | 0.2 | KE:1502 | Histone deacetylase inhibition |
AOP:306 | Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | 0.75 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
KE:286 | Altered, Transcription of genes by the androgen receptor | |||||
AOP:310 | Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR | Unclassified | - | 0.08 | KE:18 | Activation, AhR |
AOP:314 | Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE) | Immune System Disease; Musculoskeletal System Disease | Under Development | 0.2 | KE:1710 | Binding to estrogen receptor (ER)-α in immune cells |
AOP:344 | Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring | Unclassified | Under Development | 0.75 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
KE:286 | Altered, Transcription of genes by the androgen receptor | |||||
AOP:345 | Androgen receptor (AR) antagonism leading to decreased fertility in females | Endocrine System Disease; Reproductive System Disease; Reproductive System Disease | Under Development | 0.5 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
KE:286 | Altered, Transcription of genes by the androgen receptor | |||||
AOP:363 | Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure | Unclassified | Under Review | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:279 | Thyroperoxidase, Inhibition | |||||
AOP:364 | Thyroperoxidase inhibition leading to altered visual function via decreased eye size | Unclassified | Under Development | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:279 | Thyroperoxidase, Inhibition | |||||
AOP:365 | Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning | Unclassified | Under Development | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:279 | Thyroperoxidase, Inhibition | |||||
AOP:372 | Androgen receptor antagonism leading to testicular cancer | Endocrine System Disease; Reproductive System Disease; Cancer | - | 0.6 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
KE:286 | Altered, Transcription of genes by the androgen receptor | |||||
AOP:392 | Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation | Unclassified | Under Development | 0.4 | KE:1866 | Fibrinolysis, decreased |
KE:1497 | Increased, recruitment of inflammatory cells | |||||
AOP:411 | Oxidative stress Leading to Decreased Lung Function | Respiratory System Disease | - | 0.25 | KE:1392 | Oxidative Stress |
AOP:414 | Aryl hydrocarbon receptor activation leading to lung fibrosis through TGF-β dependent fibrosis toxicity pathway | Musculoskeletal System Disease; Respiratory System Disease | - | 0.2 | KE:18 | Activation, AhR |
AOP:415 | Aryl hydrocarbon receptor activation leading to lung fibrosis through IL-6 toxicity pathway | Musculoskeletal System Disease; Respiratory System Disease | - | 0.2 | KE:18 | Activation, AhR |
AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.17 | KE:18 | Activation, AhR |
AOP:417 | Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathway | Cancer | - | 0.4 | KE:18 | Activation, AhR |
KE:17 | Altered gene expression, AHR nuclear translocator (ARNT)-dependent pathway | |||||
AOP:418 | Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway | Respiratory System Disease | - | 0.4 | KE:18 | Activation, AhR |
KE:17 | Altered gene expression, AHR nuclear translocator (ARNT)-dependent pathway | |||||
AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory System Disease | - | 0.5 | KE:18 | Activation, AhR |
KE:1923 | Altered gene expression, P53 dependent apoptosis pathway | |||||
AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.5 | KE:18 | Activation, AhR |
KE:1917 | Altered gene expression, NRF2 dependent antioxidant pathway | |||||
AOP:424 | Oxidative stress Leading to Decreased Lung Function via CFTR dysfunction | Respiratory System Disease | - | 0.17 | KE:1392 | Oxidative Stress |
AOP:425 | Oxidative Stress Leading to Decreased Lung Function via Decreased FOXJ1 | Respiratory System Disease | - | 0.17 | KE:1392 | Oxidative Stress |
AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic Disease; Cancer | Under Development | 0.11 | KE:18 | Activation, AhR |
AOP:445 | Estrogen Receptor Alpha Agonism leads to Impaired Reproduction | Reproductive System Disease | - | 0.12 | KE:1065 | Activation, estrogen receptor alpha |
AOP:447 | Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways | Urinary System Disease | - | 0.17 | KE:1917 | Altered gene expression, NRF2 dependent antioxidant pathway |
KE:1392 | Oxidative Stress | |||||
AOP:455 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development | Musculoskeletal System Disease | Under Review | 0.17 | KE:18 | Activation, AhR |
AOP:456 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity | Unclassified | Under Review | 0.17 | KE:18 | Activation, AhR |
AOP:458 | AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.12 | KE:18 | Activation, AhR |
AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.33 | KE:18 | Activation, AhR |
KE:277 | Thyroid hormone synthesis, Decreased | |||||
KE:1392 | Oxidative Stress | |||||
AOP:472 | DNA adduct formation leading to kidney failure | Urinary System Disease | - | 0.11 | KE:1392 | Oxidative Stress |
AOP:477 | Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring | Physical Disorder | - | 0.67 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
AOP:494 | AhR activation leading to liver fibrosis | Gastrointestinal System Disease | - | 0.17 | KE:18 | Activation, AhR |
AOP:503 | Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation | Reproductive System Disease; Cancer | Under Review | 0.17 | KE:1065 | Activation, estrogen receptor alpha |
AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.08 | KE:2216 | Binding of antagonist to thyroid hormone receptor |
AOP:536 | Estrogen receptor agonism leading to reduced survival and population growth due to renal failure | Unclassified | - | 0.17 | KE:111 | Agonism, Estrogen receptor |
AOP:537 | Estrogen receptor agonism leads to reduced fecundity via increased vitellogenin in the liver | Unclassified | - | 0.2 | KE:111 | Agonism, Estrogen receptor |
AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive System Disease; Endocrine System Disease | - | 0.33 | KE:18 | Activation, AhR |
KE:2124 | increased, Bax expression |
TICToK is a database of tattoo ink chemicals compiled from different regulatory resources. The authors are not liable for any inaccuracies or omissions of any chemicals in this resource. Importantly, our sole goal to build this resource on tattoo ink chemicals is to enable future basic research on this topic, and it does not necessarily reflect the views or objectives of our employers or funders.